Cyclin Dependent Kinase 2 (p33 Protein Kinase or Cell Division Protein Kinase 2 or CDK2 or EC 2.7.11.22) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2021 Update

Pages: 110 Published: October 31, 2021 Report Code: GMDGDHC2997TDB

The Cyclin Dependent Kinase 2 market research report provides in depth analysis on Cyclin Dependent Kinase 2 (p33 Protein Kinase or Cell Division Protein Kinase 2 or CDK2 or EC 2.7.11.22) targeted pipeline therapeutics. The report provides comprehensive information on the Cyclin Dependent Kinase 2 (p33 Protein Kinase or Cell Division Protein Kinase 2 or CDK2 or EC 2.7.11.22) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Cyclin Dependent Kinase 2 (p33 Protein Kinase or Cell Division Protein Kinase 2 or CDK2 or EC 2.7.11.22) targeted therapeutics development with respective active and dormant or discontinued projects.

What are the key MoA in the cyclin dependent kinase 2 pipeline market?

The key MoA in the cyclin dependent kinase 2 pipeline market is Cyclin Dependent Kinase 2 Inhibitor.

What are the key RoA in the cyclin dependent kinase 2 pipeline market?

The key RoA in the cyclin dependent kinase 2 pipeline market are Oral, Intravenous, and Subcutaneous. Oral has the highest number of pipeline products in the cyclin dependent kinase 2 pipeline market.

Cyclin dependent kinase 2 pipeline market, by MoA

Cyclin dependent kinase 2 pipeline market, by MoA

For more MoA insights, download a free report sample

What are the key molecule types in the cyclin dependent kinase 2 pipeline market?

The key molecule types in the cyclin dependent kinase 2 pipeline market is small molecule.

What are the key companies in the cyclin dependent kinase 2 pipeline market?

The key companies in the cyclin dependent kinase 2 pipeline market are Adastra Pharmaceuticals Inc, Apollo Therapeutics LLC, Arc Therapeutics Inc, Astex Pharmaceuticals Inc, Aucentra Therapeutics Pty Ltd, Blueprint Medicines Corp, Cyclacel Pharmaceuticals Inc, Monte Rosa Therapeutics Inc, Neosome Life Sciences LLC, Nuvation Bio Inc, Pfizer Inc, Prous Institute for Biomedical Research SA, Rizen (Suzhou) Biosciences Co Ltd, Shanghai Junshi Bioscience Co Ltd, and Tiziana Life Sciences Plc.

Cyclin dependent kinase 2 pipeline market, by companies

Cyclin dependent kinase 2 pipeline market, by companies

To know more about key companies, download a free report sample

Market report overview

Key MoA Cyclin Dependent Kinase 2 Inhibitor

 

Key RoA Oral, Intravenous, and Subcutaneous
Key Molecule Type Small Molecule

 

Key Companies Adastra Pharmaceuticals Inc, Apollo Therapeutics LLC, Arc Therapeutics Inc, Astex Pharmaceuticals Inc, Aucentra Therapeutics Pty Ltd, Blueprint Medicines Corp, Cyclacel Pharmaceuticals Inc, Monte Rosa Therapeutics Inc, Neosome Life Sciences LLC, Nuvation Bio Inc, Pfizer Inc, Prous Institute for Biomedical Research SA, Rizen (Suzhou) Biosciences Co Ltd, Shanghai Junshi Bioscience Co Ltd, and Tiziana Life Sciences Plc

Scope

  • The report provides a snapshot of the global therapeutic landscape for Cyclin Dependent Kinase 2 (p33 Protein Kinase or Cell Division Protein Kinase 2 or CDK2 or EC 2.7.11.22)
  • The report reviews Cyclin Dependent Kinase 2 (p33 Protein Kinase or Cell Division Protein Kinase 2 or CDK2 or EC 2.7.11.22) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Cyclin Dependent Kinase 2 (p33 Protein Kinase or Cell Division Protein Kinase 2 or CDK2 or EC 2.7.11.22) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Cyclin Dependent Kinase 2 (p33 Protein Kinase or Cell Division Protein Kinase 2 or CDK2 or EC 2.7.11.22) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Cyclin Dependent Kinase 2 (p33 Protein Kinase or Cell Division Protein Kinase 2 or CDK2 or EC 2.7.11.22) targeted therapeutics

Reasons to Buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Cyclin Dependent Kinase 2 (p33 Protein Kinase or Cell Division Protein Kinase 2 or CDK2 or EC 2.7.11.22)Identify the use of drugs for target identification and drug repurposing Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Cyclin Dependent Kinase 2 (p33 Protein Kinase or Cell Division Protein Kinase 2 or CDK2 or EC 2.7.11.22) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Key Players

  • Adastra Pharmaceuticals Inc

    Apollo Therapeutics LLC

    Arc Therapeutics Inc

    Astex Pharmaceuticals Inc

    Aucentra Therapeutics Pty Ltd

    Blueprint Medicines Corp

    Cyclacel Pharmaceuticals Inc

    Monte Rosa Therapeutics Inc

    Neosome Life Sciences LLC

    Nuvation Bio Inc

    Pfizer Inc

    Prous Institute for Biomedical Research SA

    Rizen (Suzhou) Biosciences Co Ltd

    Shanghai Junshi Bioscience Co Ltd

    Tiziana Life Sciences Plc

Table of Contents

Table of Contents

Introduction

Cyclin Dependent Kinase 2 (p33 Protein Kinase or Cell Division Protein Kinase 2 or CDK2 or EC

2.7.11.22) – Overview

Cyclin Dependent Kinase 2 (p33 Protein Kinase or Cell Division Protein Kinase 2 or CDK2 or EC

2.7.11.22) – Therapeutics Development

Cyclin Dependent Kinase 2 (p33 Protein Kinase or Cell Division Protein Kinase 2 or CDK2 or EC

2.7.11.22) – Therapeutics Assessment

Cyclin Dependent Kinase 2 (p33 Protein Kinase or Cell Division Protein Kinase 2 or CDK2 or EC

2.7.11.22) – Companies Involved in Therapeutics Development

Cyclin Dependent Kinase 2 (p33 Protein Kinase or Cell Division Protein Kinase 2 or CDK2 or EC

2.7.11.22) – Drug Profiles

Cyclin Dependent Kinase 2 (p33 Protein Kinase or Cell Division Protein Kinase 2 or CDK2 or EC

2.7.11.22) – Dormant Products

Cyclin Dependent Kinase 2 (p33 Protein Kinase or Cell Division Protein Kinase 2 or CDK2 or EC

2.7.11.22) – Discontinued Products

Cyclin Dependent Kinase 2 (p33 Protein Kinase or Cell Division Protein Kinase 2 or CDK2 or EC

2.7.11.22) – Product Development Milestones

Appendix

List of Tables

List of Tables

Number of Products under Development by Stage of Development, 2021

Number of Products under Development by Therapy Areas, 2021

Number of Products under Development by Indications, 2021

Number of Products under Development by Indications, 2021 (Contd..1)

Number of Products under Development by Indications, 2021 (Contd..2)

Number of Products under Development by Companies, 2021

Products under Development by Companies, 2021

Products under Development by Companies, 2021 (Contd..1)

Products under Development by Companies, 2021 (Contd..2)

Products under Development by Companies, 2021 (Contd..3)

Products under Development by Companies, 2021 (Contd..4)

Products under Development by Companies, 2021 (Contd..5)

Number of Products under Investigation by Universities/Institutes, 2021

Products under Investigation by Universities/Institutes, 2021

Number of Products by Stage and Mechanism of Actions, 2021

Number of Products by Stage and Route of Administration, 2021

Number of Products by Stage and Molecule Type, 2021

Pipeline by Adastra Pharmaceuticals Inc, 2021

Pipeline by Apollo Therapeutics LLC, 2021

Pipeline by Arc Therapeutics Inc, 2021

Pipeline by Astex Pharmaceuticals Inc, 2021

Pipeline by Aucentra Therapeutics Pty Ltd, 2021

Pipeline by Blueprint Medicines Corp, 2021

Pipeline by Cyclacel Pharmaceuticals Inc, 2021

Pipeline by Monte Rosa Therapeutics Inc, 2021

Pipeline by Neosome Life Sciences LLC, 2021

Pipeline by Nuvation Bio Inc, 2021

Pipeline by Pfizer Inc, 2021

Pipeline by Prous Institute for Biomedical Research SA, 2021

Pipeline by Rizen (Suzhou) Biosciences Co Ltd, 2021

Pipeline by Shanghai Junshi Bioscience Co Ltd, 2021

Pipeline by Tiziana Life Sciences Plc, 2021

Dormant Products, 2021

Dormant Products, 2021 (Contd..1)

Dormant Products, 2021 (Contd..2)

Discontinued Products, 2021

List of Figures

List of Figures

Number of Products under Development by Stage of Development, 2021

Number of Products under Development by Therapy Areas, 2021

Number of Products under Development by Top 10 Indications, 2021

Number of Products by Stage and Mechanism of Actions, 2021

Number of Products by Routes of Administration, 2021

Number of Products by Stage and Routes of Administration, 2021

Number of Products by Stage and Molecule Type, 2021

Frequently Asked Questions

$3500

Can be used by individual purchaser only

$10500

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 (0) 20 7947 2960

GDPR + CCPA Compliant

Personal and transaction information are kept safe from unauthorised use.

Recently Viewed Reports

Looking to stay on top of industry & market trends?

Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.